Links to other pages within Patient UK which are related to this topic:
Experience | Medicines | Patient+ | News | Products | Other
Print options:   Other options:   (what's this?)

This is a PatientPlus article. PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.

Digoxin and the Cardiac Glycosides

Cardiac glycosides act by increasing sodium/calcium exchange. This has the effect of increasing intracellular calcium levels which in turn enhances the strength of contraction of myocardial muscle (positive ionotropism). It also affects the electrical physiology of the heart, blocking AV conduction, and reducing the heart rate by enhancing vagal nerve activity (negative chronotropy). Members of this group include digoxin, digitoxin, digitalis and oubaine. Of these, only digoxin is in regular use in the UK.

Indications

Atrial fibrillation

The principle indication is permanent/persistent atrial fibrillation with a fast ventricular rate. The target should be a resting ventricular rate of approximately 90/minute. It should be considered as monotherapy primarily for sedentary patients. Beta-blockers or rate-limiting calcium-channel blockers are more effective for monotherapy in patients likely to undergo exertion.1

Supraventricular tachycardia

Digoxin is most commonly used in this situation in children with congenital heart disease. It is given intravenously in the acute situation to slow the heart rate.

Heart Failure

NICE guidance suggests that digoxin should be used as first-line in patients with co-existing heart failure. In all other cases due to left ventricular dysfunction it should be reserved for patients in whom the condition has worsened despite the use of ACE inhibitors, beta-blockers and diuretic therapy.2

Dosage3

Initiation

Digoxin is usually given orally and rarely intravenously. It should not be given intramuscularly as absorption will be erratic. A loading dose should be given of 15mcg/kg of lean body weight, in three divided doses at 6 hourly intervals. For a woman with a lean body weight of 50kg this would work out at a total dose of 15x50=750mcg. Lean body weight is defined as total body mass minus fat mass. There are a number of methods of determining this but where it is clinically significant the simplest method in primary care is the use of skin calipers.4 Divide the total by three to give an individual dose of 250mcg. If the ventricular rate does not reduce to the desired target, an additional dose of 5mcg/kg can be given, providing there are no symptoms or signs of toxicity (see below). If the rate does not come down after a further dose another drug should be given.
Patients given a loading dose need to be monitored carefully for symptoms of toxicity and the development of arrhythmias. There are no indications in the guidelines as to how frequently patients on a loading dose should be monitored, so this will have to be determined by the clinical state of the patient. If regular monitoring is not possible a starting dose can be given of 5mcg/kg adjusted pro rata according to renal function (see below).

Maintenance

The maintenance dose is calculated as a fraction of the effective loading dose, adjusted for renal function.

Digoxin Maintenance Dosage

Creatinine clearance (ml/min)

Daily maintenance dose as a fraction of the effective loading dose

100 1/3
50 1/4
25 1/5
10 1/6
0 1/7

Cautions5
  • Recent myocardial infarction - The concern here is that digoxin can increase utilisation of oxygen by the myocardium, so although it is not contra-indicated, it should be used with caution.
  • Hypokalaemia - This sensitises the actions of digoxin on the myocardium.
  • Sick sinus syndrome - Digoxin may be unpredictable in its chronotropic actions and may cause all sorts of arrhythmias. In Sick sinus syndrome, digoxin may provoke or aggravate sinus bradycardia or cause sinoatrial block.
  • Pregnancy - No significant adverse effects on the developing fetus have been demonstrated but the dosage response may be more unpredictable than in non-pregnant women. The risks and benefits of treatment need to be carefully considered in pregnant women with heart disease. There is no contraindication to breast-feeding.
  • Thyroid disorders - The dosage may need to be reduced in myxoedema and increased in thyrotoxicosis (until the patient becomes euthyroid).
  • The elderly - This group of patients tend to have a lower BMI and reduced renal function, both of which increase the risk of toxicity. Dosage should be initiated at the lower end of the range.
  • Driving and operating machinery - The effects on the central nervous system and eyesight mean that patients should be warned about these activities.
  • Intravenous administration - This should be carried out slowly.
Contra-Indications5
  • Intermittent complete heart block or 2nd degree heart block - Digoxin should be avoided, particularly if there is a history of Stokes-Adams attacks.
  • Ventricular fibrillation or tachycardia - The negative chronotropic effect of digoxin would be dangerous in these conditions.
  • Arrythmias with accessory pathways - Wolff-parkinson-white syndrome is a common example of these conditions. Digoxin is contra-indicated because it will impair conduction in the normal pathways without affecting the accessory pathways.
  • Left ventricular outflow obstruction - Examples here include aortic stenosis and hypertrophic obstructive cardiomyopathy. The positive ionotropic effect would aggravate the demand on the ventricular myocardium to contract against the obstruction. The exception may be some patients with co-existent atrial fibrillation or heart failure, but specialist advice would be required.
Side-Effects5
  • Arrythmias - Common arrythmias include ventricular ectopics, atrial premature beats, ventricular bigeminy / trigeminy and atrial tachycardia with complete heart block
  • Visual disturbance - yellow vision (xanthopsia), blurred vision, photophobia
  • Gastrointestinal effects - abdominal pain, poor appetite, nausea, diarrhoea
  • Gynaecomastia
  • Central nervous system effects - Weakness, dizziness, confusion, apathy, fatigue, malaise, headache, depression, psychosis
  • Rare effects - Bowel ischaemia, thrombocytopaenia, skin rashes
Monitoring

Monitoring is important both to ensure that the correct dosage is being given and also that factors which might provoke toxicity - e.g. renal dysfunction and hypokalaemia - are not developing. Urea and electrolytes should be monitored. In stable patients this may be done annually, but if there is any change in dosage or clinical status more regular monitoring should be performed.

The best monitor of response to treatment in atrial fibrillation is ventricular rate. Plasma concentrations can however be helpful when initiating therapy, checking compliance or detecting toxicity. A target range of 1.0-1.5nml/l should be aimed for but concentrations of 2nm/l may be required in atrial fibrillation. Levels above 2nm/l suggest toxicity. Plasma potassium should be measured in all cases of suspected toxicity. If hypokalaemia is evident, the drug should be withheld irrespective of the digoxin level.

Interactions5
  • Drugs causing potassium depletion - Potassium-sparing diuretics should be used. Apart from diuretics, lithium salts, carbenoxolone (now withdrawn) and corticosteroids can also cause potassium depletion.
  • Drugs causing an increase in digoxin level - These include amiodarone, diltiazem, verapamil, itraconazole, quinidine, and spironolactone. Amiodarone has the greatest effect of this group and some authorities recommend avoiding it altogether. In all cases, digoxin levels should be monitored closely.
  • Drugs affecting the breakdown of digoxin in the gut - In about 10% of patients, digoxin is metabolised by the gut intestinal bacteria, mainly Eubacterium glenum. Antibiotics such as erythromycin, clarithromycin, and tetracycline can inhibit this breakdown and thus increase the systemic availability of digoxin.

Document references
  1. The management of atrial fibrillation, NICE Clinical Guideline (Jun 2006)
  2. Management of chronic heart failure in adults in primary and secondary care. NICE (July 2003)
  3. The Use of Digoxin (Factfile) British Heart Foundation (7/2001)
  4. Lean Body Mass; Medscape 2007
  5. Summary of Product Characteristics - Lanoxin® Tablets 0.25mg, (digoxin) GlaxoSmithKline UK, Electronic Medicines Compendium Updated 21 May 2003
AcknowledgementsEMIS is grateful to Dr Laurence Knott for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2008.
DocID: 2985
Document Version: 3
DocRef: bgp24528
Last Updated: 9 Aug 2007
Review Date: 8 Aug 2008

The authors and editors of this article are employed to create accurate and up to date content reflecting reliable research evidence, guidance and best clinical practice. They are free from any commercial conflicts of interest.

Find out more about updating.

(what's this?)

Patient UK Current Health News

Advertisements











Disclaimer: Patient UK has no control over the content of any external links above. Inclusion does not imply endorsement by Patient UK.

Want to advertise on this site? Find out how >>

Clicking here will take you to the foot of this page where you'll find a list of Information Leaflets which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of Support Groups which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of Medicines & Drugs which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of diagrams which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of PatientPlus (detailed reference) articles which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of UK Guidelines which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of other selected websites which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of Poems and Stories which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of Operations and Procedures which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find a list of Online Videos which are related to the topic you are currently viewing
Clicking here will take you to the foot of this page where you'll find links through to our interactive forum.
Here you can follow a link to view existing patient experiences on this subject, or to add your own
Clicking here will take you to the foot of this page where you'll find links to news stories on this subject in our Online Newspaper
Clicking here will take you to the foot of this page where you'll find links to related products
Clicking here will take you to the foot of this page where you'll find links to other useful sources of information
Click here to open a printer-friendly version of this document, in a new window, together with the print dialogue box
Click here to open this document in PDF format
This will offer you the usual PDF options i.e. document navigation, search, zoom and formatted print
Note: this is the best way to print the document
Click here to listen to the MP3 audio recording of this document
Click here to download the audio recording of this document as a podcast, for listening to at your leisure
Click here to open our Dictionaries and Glossaries page
Click here to see related products in our Online Pharmacy
Note: this will open in a new window
Click here to add this page to a social bookmarking site of your choice
Click here if you want to find out more about social bookmarking. This link will take you to the Wikipedia explanation
Note: this will open in a new window
Click here to return to the home page
Click here to read our 'About Us' page
Go to the Emis Access website, where you can book an appointment with your GP, order a repeat prescription or view you medical record online.
Note: this will open in a new window
View and/or join in discussion about health, lifestyle and disease in our interactive forum.
Note: this will open in a new window
Go to our online pharmacy where you can buy over-the-counter products for home delivery.
Note: this will open in a new window
Go to our online newspaper for current medical news and commentary.
Note: this will open in a new window
Adverts on this site do not influence the medical content. Click to read more.
Adverts on this site do not influence the medical content. Click to read more.